Abstracts tagged "Lupus nephritis"

Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 2381 • ACR Convergence 2025
Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Angela Lu¹, Daming Shao², Ying Jin¹, Luis Chiriboga³, Ming Wu⁴, James Pullman⁵, Anna Broder⁶ and Shudan Wang⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Chicago, Chicago, IL, ³NYU Langone Medical Center, New York City, ⁴Northwell Health, New Hyde Park, ⁵Montefiore Medical Center, Bronx, NY, ⁶Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: The complement system is known to play a central role in the pathogenesis of lupus nephritis (LN), one of the most severe manifestations of…
Abstract Number: 1546 • ACR Convergence 2025
Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Urvi Zala¹ and Rushi Patel², ¹Loyola MacNeal Hospital, Berwyn, IL, Oak Park, IL, ²Baptist Hospitals of Southeast Texas, Beumont, TX
Background/Purpose: Lupus nephritis (LN) is seen in approximately 40–60 % of patients with systemic lupus erythematosus (SLE) and contributes significantly to morbidity and mortality in…
Abstract Number: 1467 • ACR Convergence 2025
Risk Factors Associated with Chronic Kidney Disease and End-Stage Kidney Disease in Patients with Newly Diagnosed Lupus Nephritis
Aakash V. Patel¹, Lingxiao Zhang², Hyon K. Choi³ and April Jorge⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Lupus nephritis (LN) affects over half of patients with systemic lupus erythematosus (SLE) and is associated with an increased risk for adverse kidney outcomes.…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0610 • ACR Convergence 2025
The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes
Emma Trachman¹, Amanda Eudy² and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: The ACR recommends against pregnancy in patients with SLE with high disease activity. These recommendations do not distinguish between the various manifestations of active…
Abstract Number: 2462 • ACR Convergence 2025
Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Pooja Patel¹, Eveline Wu², Laura Cannon³, Kristen Hayward⁴, Daryl Okamura⁵, Marietta De Guzman⁶, Ana Luiza Altaffer⁶, Stacy Ardoin⁷, Ellen Cody⁸, Takanobu Nadai⁹, Kei Irie⁹, Gabrielle Morgan¹⁰, Carolina Pastrana³, Angela Merritt⁹, Catherine Robben⁹, A. Carmela Sagcal-Gironella¹¹, Junfang Zhao⁹, Hermine Brunner¹² and Tomoyuki Mizuno⁹, ¹Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²UNC Chapel Hill, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Baylor College of Medicine, Houston, TX, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, ¹⁰Ann & Robert H. Lurie Children's Hospital, Chicago, IL, ¹¹Hackensack University Medical Center, Hackensack, NJ, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The safety and effectiveness of MMF for the treatment of LN have been tested in adult and pediatric patients. MMF, a prodrug, is rapidly…
Abstract Number: 2210 • ACR Convergence 2025
Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
Dahima Cintron¹, Amanda Eudy², Michelle Petri³, Rebecca Fischer-Betz⁴, Abeer Mockbel⁵, Cecilia Nalli⁶, Laura Andreoli⁷, Angela Tincani⁸, Yair Molad⁹, Dafna D. Gladman¹⁰, Murray Urowitz¹¹, Stephen Balevic¹² and Megan Clowse¹³, ¹Duke Health, Durham, NC, ²Duke University, Raleigh, NC, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁵Cairo University/Kasr- AlAiny Medical School, Cairo, Egypt, ⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁷University of Brescia, Brescia, Brescia, Italy, ⁸ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ⁹Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Duke University, Durham, NC, ¹³Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE experience higher rates of adverse pregnancy outcomes. Among those with active SLE during pregnancy, lupus nephritis (LN) is associated with particularly…
Abstract Number: 1544 • ACR Convergence 2025
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Megha Kotha³ and Wael Jarjour⁴, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN), is the most sever organ manifestation of systemic lupus erythematosus (SLE) and it contributes significantly to morbidity and mortality. . Standard…
Abstract Number: 1283 • ACR Convergence 2025
Impact of Guideline Concordant Care of Renal Outcomes in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Orysya Soroka², Mangala Rajan², Karen Onel³, Monika Safford² and Iris Navarro-Millan⁴, ¹Weill Cornell Medical Center, New York, NY, ²Weill Cornell Medicine, New York, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: End-stage renal disease (ESRD) is a serious complication of lupus nephritis (LN), yet the effect of guideline-concordant care on this outcome is unclear. Despite…
Abstract Number: 0663 • ACR Convergence 2025
iPSC-Derived Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
Parastoo Fazeli¹, Jennifer Medlin², Andrew BitMansour³, Debra Zack⁴, Rebecca Elstrom⁵, Bertha Villa⁵, Lilly Wong⁶, John Goulding⁷, Nicholas Brookhouser⁵, Trever Greene⁵, Cara Bickers⁵, Carol Wong⁵, Beatrice Ferguson⁵, Tom Lee⁵, Jode Goodridge⁵, Marie Hu⁸, Veronika Bachanova⁸, Jeffrey Miller⁹, Bahram Valamehr⁶, Matthew Lunning¹⁰ and Vaneet Sandhu⁵, ¹UMN, ST PAUL, MN, ²University of Nebraska Medical Center, Omaha, NE, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., Solana Beach, CA, ⁵Fate Therapeutics, Inc., San Diego, ⁶Fate Therapeutics, Inc., San Diego, CA, ⁷Fate Therapeutics, San Diego, ⁸University of Minnesota, Minneapolis, ⁹University of Minnesota, Minneaspolis, MN, ¹⁰University of Nebraska, Omaha
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy shows promise in autoimmune disease. However, autologous CAR T-cell therapy is limited by prolonged pre- and…
Abstract Number: 0611 • ACR Convergence 2025
Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Fadi Kharouf¹, Pankti Mehta², Qixuan Li², Dafna D. Gladman³, Laura Whitall Garcia⁴ and Zahi Touma⁵, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Venous thromboembolism (VTE) is a known complication of systemic lupus erythematosus (SLE), yet there is a lack of high-quality studies specifically focused on lupus…
Abstract Number: 1258 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Ana Serrano-Combarro¹, Belén Atienza-mateo², Leticia del Olmo Perez³, Sara García-Perez⁴, Guillermo Gonzalez Mozo de Rosales⁵, Jose Rosas Gómez de Salazar⁶, ana Urruticoechea-Arana⁷, Andrea García-Valle⁸, Jesús Loarce⁹, Paula García-Escudero¹⁰, Bryan Josué Flores Robles¹¹, Rafael B. Melero-González¹², Alicia Garcia¹³, Maria Martín López¹⁴, Patricia López Viejo¹⁵, Maria Jose Perez Gaan¹⁶, Nuria Vegas Revenga¹⁷, Angel Garcia-Aparicio¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Juan Moreno Morales²⁰ and Ricardo Blanco²¹, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³HGU Nuestra Señora del Prado, Talavera de la Reina, Talavera de la Reina, Spain, ⁴Complejo Hospitalario de Vigo, Vigo, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁸Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰Hospital Universitario Álava, Bilbao, Spain, ¹¹Hospital San Pedro, Logroño, Spain, ¹²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ¹³Rheumatologist, La Laguna, Spain, ¹⁴Hospital ¹² de Octubre, Madrid, Spain, ¹⁵Hospital Severo Ochoa (Leganés), Leganes, Spain, ¹⁶Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁷Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹⁸Hospital Universitario de Toledo, Toledo, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are usually the recommended drugs. JAK inhibitors (JAKi)…
Abstract Number: 1853 • ACR Convergence 2025
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Yevgeniya Gartshteyn¹, Daniel Portnoy², Matthieu Paiola³, Anca Askanase² and Adam Mor⁴, ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³Columbia University Irving Medical Center, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…
Abstract Number: 1540 • ACR Convergence 2025
Association of Hypoalbuminemia with Serious Infections in Systemic Lupus Erythematosus Patients Receiving Dialysis
Ping Hsuan Kuo¹, Pu Jun Fang², Chien-Chih Lai³ and Yi-Syuan Sun⁴, ¹Taipei Veteran General Hospital, Taipei City, Taiwan (Republic of China), ²Tri-Service General Hospital, Hukou Township, Taiwan (Republic of China), ³Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ⁴taipei VGHTPE, ???, Taiwan (Republic of China)
Background/Purpose: Lupus nephritis, a key manifestation of systemic lupus erythematosus (SLE), can progress to end-stage kidney disease and increase patient burden. While patients with SLE…

1
2
3
…
43
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].